Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

322P - Small extracellular vesicle miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer

Date

28 Mar 2025

Session

Poster Display session

Presenters

Wei Zhang

Citation

Journal of Thoracic Oncology (2025) 20 (3): S181-S207. 10.1016/S1556-0864(25)00632-X

Authors

W. Zhang1, Y. Li2, D. Wang1, X. Wu1, D. Zhang3, F. Zhang3, D. Liu3, X. Xu3, Y. Zhang4, F. Qian4, B. Han4

Author affiliations

  • 1 Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, shanghai/CN
  • 2 Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai/CN
  • 3 Department of Clinical and Translational Medicine, 3D Medicines Inc, Shanghai/CN
  • 4 Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 322P

Background

Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive neuroendocrine tumor characterized by rapid growth and early metastasis. The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has become the standard treatment. However, the lack of predictive biomarkers remains a significant barrier to personalized treatment. This study aimed to investigate whether small extracellular vesicle (sEV)-derived microRNAs (miRNAs) could serve as predictive biomarkers for the efficacy of immunochemotherapy in ESSCLC patients.

Methods

We prospectively collected clinical data and serum samples from chemotherapy-naïve ES-SCLC patients at Shanghai Chest Hospital, who were subsequently treated with chemoimmunotherapy. Serum sEV miRNAs were isolated and sequenced prior to treatment. Differential expression analysis was performed to identify miRNAs that were differentially expressed between treatment responders and non-responders. Machine learning algorithms were applied to develop predictive models for treatment response.

Results

The screening identified 10 candidate miRNAs, three of which were overexpressed in responders and seven in non-responders. Functional enrichment analysis revealed the biological significance of these differentially expressed sEV miRNAs, including hsa-miR-125a-5p and hsa-miR-150-5p, et al. Among the eight predictive models tested, the Extra Trees algorithm demonstrated superior accuracy, achieving a mean AUC of 0.848, sensitivity of 0.82, specificity of 0.72, and a cutoff value of 0.61. These results suggest its potential for clinical application in prospective samples.

Conclusions

Our research demonstrated that sEV-derived miRNAs have potential as predictive biomarkers for immunochemotherapy outcomes in ES-SCLC. The Extra Trees model represented a valuable tool for personalizing treatment strategies, which could advance precision medicine for ES-SCLC patients.

Legal entity responsible for the study

The authors.

Funding

National Natural Science Foundation of China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.